EZH2 and B-cell chronic lymphocytic leukemia: More interesting, however, was the finding that within U-CLL high EZH2 expression and TP53 aberrations showed little overlap, highlighting EZH2 overexpression as a potential p53-independent pathomechanism of clinical aggressiveness.